Wesana Health Announces Listing on OTCQB® Venture Market

NEXT STORY
Proteinase K Market Research Report by Therapeutic Area, by Form, by Region – Global Forecast to 2026 – Cumulative Impact of COVID-19
PREV STORY
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, “Off-the-Shelf”, Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017

NEW YORK, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage ...

author_avatar
NASDAQ Market News

Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic ...

author_avatar
NASDAQ Market News

Rejuvenate Reverses Muscle Loss From Aging Without Exercise

author_avatar
NASDAQ Market News